Clinical efficacy of piperacillin/tazobactam in the treatment of complicated skin and soft tissue infections

References

• Hersh AL, Chambers HF, Maselli JH, et al. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008;168:1585–1591.
   PubMed Web of Science ®Google Scholar
• Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008;51:291–298.
   PubMed Web of Science ®Google Scholar
• Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009;15:1516–1518.
   PubMed Web of Science ®Google Scholar
• Miller LG, Eisenberg DF, Liu H, et al. Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005–2010. BMC Infect Dis. 2015;15:362.
   PubMed Web of Science ®Google Scholar
• Esposito S, Noviello S, Leone S. Epidemiology and microbiology of skin and soft tissue infections. Curr Opin Infect Dis. 2016;29:109–115.
   PubMed Web of Science ®Google Scholar
• Napolitano LM. Severe soft tissue infections. Infect Dis Clin North Am. 2009;23:571–591.
   PubMed Web of Science ®Google Scholar
• Caínzos M. Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections–are they applicable today? Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2008;14(Suppl 6):9–18.
   PubMed Web of Science ®Google Scholar
• Astagneau P, Rioux C, Golliot F, et al. Morbidity and mortality associated with surgical site infections: results from the 1997–1999 INCISO surveillance. J Hosp Infect. 2001 Aug;48(4):267–274.
   PubMed Web of Science ®Google Scholar
• Stephens JM, Gao X, Patel DA, et al. Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. Clin Outcomes Res CEOR. 2013;5:447–457.
   PubMedGoogle Scholar
• Hatoum HT, Akhras KS, Lin S-J. The attributable clinical and economic burden of skin and skin structure infections in hospitalized patients: a matched cohort study. Diagn Microbiol Infect Dis. 2009;64:305–310.
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e10–52. .
   PubMed Web of Science ®Google Scholar
• Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagn Microbiol Infect Dis. 2007;57:7–13.
   PubMed Web of Science ®Google Scholar
• Jones ME, Karlowsky JA, Draghi DC, et al. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents. 2003;22:406–419.
   PubMed Web of Science ®Google Scholar
• Garau J, Ostermann H, Medina J, et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect. 2013;19:E377–85.
   PubMed Web of Science ®Google Scholar
• Zervos MJ, Freeman K, Vo L, et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol. 2012;50:238–245.
   PubMed Web of Science ®Google Scholar
• Li X, Chen Y, Gao W, et al. Epidemiology and outcomes of complicated skin and soft tissue infections among inpatients in Southern China from 2008 to 2013. Plos One. 2016;11:e0149960.
   PubMed Web of Science ®Google Scholar
• Merlino JI, Malangoni MA. Complicated skin and soft-tissue infections: diagnostic approach and empiric treatment options. Cleve Clin J Med. 2007;74(Suppl 4):S21–28.
   PubMedGoogle Scholar
• Phakade RS, Nataraj G, Kuyare SS, et al. Is methicillin-resistant Staphylococcus aureus involved in community acquired skin and soft tissue infections? Experience from a tertiary care centre in Mumbai. J Postgrad Med. 2012;58:3–7.
   PubMed Web of Science ®Google Scholar
• Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65(Suppl 3):iii35–44.
   PubMed Web of Science ®Google Scholar
• Talbot GH, Bradley J, Edwards JE, et al. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin Infect Dis. 2006;42:657–668.
   PubMed Web of Science ®Google Scholar
• Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs. 2003;63:1459–1480.
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Berendt AR, Cornia PB, et al. Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;2012(54):e132–73.
   Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–55.
   PubMed Web of Science ®Google Scholar
• D’Angelo RG, Johnson JK, Bork JT, et al. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria. Expert Opin Pharmacother. 2016;17:953–967.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Lourida P, Poulikakos P, et al. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014;58:654–663.
   PubMed Web of Science ®Google Scholar
• Morrill HJ, Pogue JM, Kaye KS, et al. Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis. 2015;2:ofv050.
   PubMed Web of Science ®Google Scholar
• Kinzig M, Sörgel F, Brismar B, et al. Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob Agents Chemother. 1992;36:1997–2004.
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Roberts JA, Paterson DL, et al. Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol. 2010;6:1017–1031.
   PubMed Web of Science ®Google Scholar
• Legat FJ, Krause R, Zenahlik P, et al. Penetration of piperacillin and tazobactam into inflamed soft tissue of patients with diabetic foot infection. Antimicrob Agents Chemother. 2005;49:4368–4371.
   PubMed Web of Science ®Google Scholar
• Doi Y, Chambers HF. Penicillins and β-lactamase inhibitors. In Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 8th ed. Philadelphia: Saunders, 2015.
   Google Scholar
• Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis. 2015;60:1319–1325.
   PubMed Web of Science ®Google Scholar
• Kang C-I, Park SY, Chung DR, et al. Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Infect. 2012;64:533–534.
   PubMed Web of Science ®Google Scholar
• Tassler H, Cullmann W, Elhardt D. Therapy of soft tissue infections with piperacillin/tazobactam. J Antimicrob Chemother. 1993;31(Suppl A):105–12.
   PubMed Web of Science ®Google Scholar
• Zeillemaker AM, Veldkamp KE, van Kraaij MG, et al. Piperacillin/tazobactam therapy for diabetic foot infection. Foot Ankle Int. 1998;19:169–172.
   PubMed Web of Science ®Google Scholar
• Sanders WE, Sanders CC. Piperacillin/tazobactam: a critical review of the evolving clinical literature. Clin Infect Dis. 1996;22:107–123.
   PubMed Web of Science ®Google Scholar
• Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 2002;34:1460–1468.
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Armstrong DG, Citron DM, et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet Lond Engl. 2005;366:1695–1703.
   PubMed Web of Science ®Google Scholar
• Xu Z-R, Ran X-W, Xian Y, et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial. J Antimicrob Chemother. 2016;71:1688–1696.
   PubMed Web of Science ®Google Scholar
• Giordano P, Song J, Pertel P, et al. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents. 2005;26:357–365.
   PubMed Web of Science ®Google Scholar
• Gyssens IC, Dryden M, Kujath P, et al. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. J Antimicrob Chemother. 2011;66:2632–2642.
   PubMed Web of Science ®Google Scholar
• Siami G, Christou N, Eiseman I, et al. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob Agents Chemother. 2001;45:525–531.
   PubMed Web of Science ®Google Scholar
• Harkless L, Boghossian J, Pollak R, et al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg Infect. 2005;6:27–40.
   PubMedGoogle Scholar
• Saltoglu N, Dalkiran A, Tetiker T, et al. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. Clin Microbiol Infect. 2010;16:1252–1257.
   PubMed Web of Science ®Google Scholar
• Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother. 2003;52:538–542.
   PubMed Web of Science ®Google Scholar
• Doi Y, Chambers HF. Other β-lactam antibiotics. In Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 8th ed. Philadelphia: Saunders, 2015.
   Google Scholar
• An MM, Zou Z, Shen H, et al. Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials. BMC Infect Dis. 2009;9:193.
   PubMed Web of Science ®Google Scholar
• Guay DR. Moxifloxacin in the treatment of skin and skin structure infections. Ther Clin Risk Manag. 2006;2:417–434.
   PubMedGoogle Scholar
• Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother. 1999;43(Suppl B):83–90.
   PubMed Web of Science ®Google Scholar
• Hooper DC. Strahilevitz. Quinolones. In Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 8th ed. Philadelphia: Saunders, 2015.
   Google Scholar
• FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. [cited 2016 Nov 30]. Available from:http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm
   Google Scholar
• Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs. 2002;62:13–59.
   PubMed Web of Science ®Google Scholar
• Harris AD, Perencevich E, Roghmann M-C, et al. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother. 2002;46:854–858.
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999;43:1379–1382.
   PubMed Web of Science ®Google Scholar
• Zervos MJ, Hershberger E, Nicolau DP, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991–2000. Clin Infect Dis. 2003;37:1643–1648.
   PubMed Web of Science ®Google Scholar
• Chang H-J, Hsu P-C, Yang -C-C, et al. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case-control study. J Microbiol Immunol Infect. 2011;44:125–130.
   PubMedGoogle Scholar
• McLaughlin M, Advincula MR, Malczynski M, et al. Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae. Antimicrob Agents Chemother. 2013;57:5131–5133.
   PubMed Web of Science ®Google Scholar